Policy Prescriptions: User Fees, EMA Worries, PBM Strategies, PRIME Milestones

The US has plenty of new pharma legislation, Europe has plenty of worries about EMA's Brexit move, pharmacy benefit managers give plenty more scrutiny to which products earn a place on formulary. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.

Policy Prescriptions

Conventional wisdom is that Washington DC, and the US Congress, experience an August doldrums each year. The Senate shook up that scenario Aug. 3, clearing not just the FDA user fee reauthorization package, but three other pieces of legislation impacting biopharma as well.

Most importantly, the user fee legislation, already passed by the House of Representatives, should head soon to the President's desk...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip